Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Safety and efficacy of the simultaneous administration of udenafil and an α-blocker in men with erectile dysfunction concomitant with BPH/LUTS

International Journal of Impotence Research volume 21, pages 122–128 (2009)Cite this article

Abstract

We evaluated the clinical efficacy and safety of administering udenafil (5-[2-propyloxy-5-(1-methyl-2-pyrollidinylethylamidosulphonyl)phenyl]-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo(4,3-d)-pyrimidin-7-one) in patients with comorbid benign prostatic hyperplasia (BPH) and erectile dysfunction (ED). One hundred and twenty patients who had been undergoing stable α-blocker therapy for BPH were enrolled in this trial and they were administered 100 mg udenafil for 8 weeks. Changes in blood pressure (BP), heart rate (HR), the international prostatic symptom score (IPSS) and the international index of ED (IIEF-5) were evaluated every 4 weeks. At end point, there was no significant change in BP and HR, whereas the lower urinary tract symptoms (LUTS) and ED improved significantly compared with baseline (IPSS 14.3–11.5, IIEF-5 11.95–18.32, P<0.05). Most patients were tolerant to the treatment and there was no evidence of additional side effects related to coadministration. The coadministration of udenafil and an α-blocker in patients with comorbid BPH and ED was safe and gave significant improvements in both LUTS and ED.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Braun M, Wassmer G, Klotz T, Reifenrath B, Mathers M, Engelmann U . Epidemiology of erectile dysfunction: results of the ‘Cologne Male Survey’. Int J Impot Res 2000; 12: 305–311.

    Article  CAS  PubMed  Google Scholar 

  2. Hoesl CE, Woll EM, Burkart M, Altwein JE . Erectile dysfunction (ED) is prevalent, bothersome and underdiagnosed in patients consulting urologists for benign prostatic syndrome (BPS). Eur Urol 2005; 47: 511–517.

    Article  CAS  PubMed  Google Scholar 

  3. Carson CC . Combination of phosphodiesterase-5 inhibitors and alpha-blockers in patients with benign prostatic hyperplasia: treatments of lower urinary tract symptoms, erectile dysfunction, or both? BJU Int 2006; 97 (Suppl 2): 39–43; discussion 44–35.

    Article  CAS  PubMed  Google Scholar 

  4. Giuliano F . Lower urinary tract symptoms and sexual dysfunction: a common approach. BJU Int 2008; 101 (Suppl 3): 22–26.

    Article  CAS  PubMed  Google Scholar 

  5. McVary K . Lower urinary tract symptoms and sexual dysfunction: epidemiology and pathophysiology. BJU Int 2006; 97 (Suppl 2): 23–28; discussion 44–25.

    Article  PubMed  Google Scholar 

  6. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol 2003; 170: 530–547.

    Article  Google Scholar 

  7. Wespes E, Amar E, Hatzichristou D, Hatzimouratidis K, Montorsi F, Pryor J et al. EAU Guidelines on erectile dysfunction: an update. Eur Urol 2006; 49: 806–815.

    Article  PubMed  Google Scholar 

  8. Chung BH, Hong SJ . Long-term follow-up study to evaluate the efficacy and safety of the doxazosin gastrointestinal therapeutic system in patients with benign prostatic hyperplasia with or without concomitant hypertension. BJU Int 2006; 97: 90–95.

    Article  CAS  PubMed  Google Scholar 

  9. Nordling J . Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia. BJU Int 2005; 95: 1006–1012.

    Article  CAS  PubMed  Google Scholar 

  10. Paick JS, Kim SW, Yang DY, Kim JJ, Lee SW, Ahn TY et al. The efficacy and safety of udenafil, a new selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction. J Sex Med 2008; 5: 946–953.

    Article  CAS  PubMed  Google Scholar 

  11. Reffelmann T, Kloner RA . Pharmacotherapy of erectile dysfunction: focus on cardiovascular safety. Expert Opin Drug Saf 2005; 4: 531–540.

    Article  CAS  PubMed  Google Scholar 

  12. Auerbach SM, Gittelman M, Mazzu A, Cihon F, Sundaresan P, White WB . Simultaneous administration of vardenafil and tamsulosin does not induce clinically significant hypotension in patients with benign prostatic hyperplasia. Urology 2004; 64: 998–1003; discussion 1003–1004.

    Article  PubMed  Google Scholar 

  13. Kloner RA, Jackson G, Emmick JT, Mitchell MI, Bedding A, Warner MR et al. Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men. J Urol 2004; 172: 1935–1940.

    Article  PubMed  Google Scholar 

  14. Doh H, Shin CY, Son M, Ko JI, Yoo M, Kim SH et al. Mechanism of erectogenic effect of the selective phosphodiesterase type 5 inhibitor, DA-8159. Arch Pharm Res 2002; 25: 873–878.

    Article  CAS  PubMed  Google Scholar 

  15. Salem EA, Kendirci M, Hellstrom WJ . Udenafil, a long-acting PDE5 inhibitor for erectile dysfunction. Curr Opin Investig Drugs 2006; 7: 661–669.

    CAS  PubMed  Google Scholar 

  16. McVary KT, Monnig W, Camps Jr JL, Young JM, Tseng LJ, van den Ende G . Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol 2007; 177: 1071–1077.

    Article  CAS  PubMed  Google Scholar 

  17. Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L . Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol 2008; 180: 1228–1234.

    Article  CAS  PubMed  Google Scholar 

  18. Stief CG, Porst H, Neuser D, Beneke M, Ulbrich E . A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 2008; 53: 1236–1244.

    Article  CAS  PubMed  Google Scholar 

  19. Greco KA, McVary KT . The role of combination medical therapy in benign prostatic hyperplasia. Int J Impot Res 2008; 20 (Suppl 3): S33–S43.

    Article  CAS  PubMed  Google Scholar 

  20. Oger S, Behr-Roussel D, Gorny D, Charles Tremeaux J, Combes M, Alexandre L et al. Combination of alfuzosin and tadalafil exerts in vitro an additive relaxant effect on human corpus cavernosum. J Sex Med 2008; 5: 935–945.

    Article  CAS  PubMed  Google Scholar 

  21. Kaplan SA, Gonzalez RR, Te AE . Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol 2007; 51: 1717–1723.

    Article  CAS  PubMed  Google Scholar 

  22. van Dijk M, Skrekas T, de la Rosette JJ . The association between lower urinary tract symptoms and sexual dysfunction: fact or fiction? Curr Opin Urol 2005; 15: 39–44.

    Article  PubMed  Google Scholar 

  23. Lund-Johansen P, Kirby RS . Effect of doxazosin GITS on blood pressure in hypertensive and normotensive patients: a review of hypertension and BPH studies. Blood Press Suppl 2003; 1: 5–13.

    Article  PubMed  Google Scholar 

  24. Jackson G, Rosen RC, Kloner RA, Kostis JB . The second Princeton consensus on sexual dysfunction and cardiac risk: new guidelines for sexual medicine. J Sex Med 2006; 3: 28–36; discussion 36.

    Article  CAS  PubMed  Google Scholar 

  25. Kloner RA . Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-blocker interactions. Am J Cardiol 2005; 96: 42M–46M.

    Article  CAS  PubMed  Google Scholar 

  26. Shim HJ, Kim YC, Park KJ, Kim DS, Kwon JW, Kim WB et al. Pharmacokinetics of DA-8159, a new erectogenic, after intravenous and oral administration to rats: hepatic and intestinal first-pass effects. J Pharm Sci 2003; 92: 2185–2195.

    Article  CAS  PubMed  Google Scholar 

  27. Shim HJ, Lee EJ, Kim SH, Kim SH, Yoo M, Kwon JW et al. Pharmacokinetics, stability, and blood partition of DA-8159, a new phosphodiesterase V inhibitor. Res Commun Mol Pathol Pharmacol 2000; 108: 275–286.

    CAS  PubMed  Google Scholar 

  28. Kim BH, Lim HS, Chung JY, Kim JR, Lim KS, Sohn DR et al. Safety, tolerability and pharmacokinetics of udenafil, a novel PDE-5 inhibitor, in healthy young Korean subjects. Br J Clin Pharmacol 2008; 65: 848–854.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Roehrborn CG . Alfuzosin: overview of pharmacokinetics, safety, and efficacy of a clinically uroselective alpha-blocker. Urology 2001; 58: 55–63; discussion 63–54.

    Article  CAS  PubMed  Google Scholar 

  30. McMurray JG, Feldman RA, Auerbach SM, Deriesthal H, Wilson N . Long-term safety and effectiveness of sildenafil citrate in men with erectile dysfunction. Ther Clin Risk Manag 2007; 3: 975–981.

    CAS  PubMed  PubMed Central  Google Scholar 

  31. Flannery MT, Ramsdell J, Ranhosky A, Davidai G, Ruoff G . Efficacy and safety of tamsulosin for benign prostatic hyperplasia: clinical experience in the primary care setting. Curr Med Res Opin 2006; 22: 721–730.

    Article  CAS  PubMed  Google Scholar 

  32. McVary KT . Alfuzosin for symptomatic benign prostatic hyperplasia: long-term experience. J Urol 2006; 175: 35–42.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This study was sponsored by Dong-A Pharmaceutical Company, Korea.

Author information

Authors and Affiliations

  1. Department of Urology, Yonsei University Health System, Seoul, Korea

    B H Chung, S H Lee & S J Yoo

  2. Department of Urology, College of Medicine, The Catholic University of Korea, Seoul, Korea

    J Y Lee

  3. Department of Urology, College of Medicine, Eulji University, Daejeon, Korea

    S W Lee

  4. Department of Urology, College of Medicine, Hallym University, Chuncheon, Korea

    C Y Oh

Authors
  1. B H Chung
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J Y Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S H Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S J Yoo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S W Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C Y Oh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C Y Oh.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chung, B., Lee, J., Lee, S. et al. Safety and efficacy of the simultaneous administration of udenafil and an α-blocker in men with erectile dysfunction concomitant with BPH/LUTS. Int J Impot Res 21, 122–128 (2009). https://doi.org/10.1038/ijir.2009.2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ijir.2009.2

Keywords

This article is cited by

Search

Advanced search

Quick links